Danaher Corporation's stock fell 9% in premarket trading following a weaker than expected Q3 core revenue growth forecast, despite the company beating Q2 earnings estimates.

Q2 Financial Results

The firm reported adjusted EPS of $1.94, exceeding the consensus estimate of $1.84 by 10 cents. Revenue reached $6.3 billion, surpassing the forecast of $6.1 billion and marking a 5.5% increase year-over-year. Core revenue advanced 3.0% compared to the previous year, or 4.5% excluding respiratory testing revenue. Free cash flow rose approximately 15.5% to $1.3 billion, supported by operating cash flow of $1.5 billion.

Danaher lifted its full-year 2026 adjusted EPS guidance to a range of $8.45 to $8.60, slightly above the analyst consensus of $8.50. It also projected core revenue growth for the full year between 3.0% and 4.0%.

Guidance and Segment Performance

The company's Q3 core revenue growth outlook of 2% to 3% disappointed investors who had anticipated a stronger acceleration. CEO Rainer Blair highlighted that Q2 marked the strongest quarter in years for the Life Sciences segment, which posted 5.5% core revenue growth. Biotechnology and Diagnostics grew 2.5% and 2.0%, respectively.

Bioprocessing orders expanded by a mid-teen percentage during the quarter, although revenue from this area was affected by the timing of customer projects.

  • Q2 revenue: $6.3 billion, up 5.5% YoY
  • Adjusted EPS: $1.94, up 8.0% YoY
  • Free cash flow: $1.3 billion, up 15.5% YoY
  • Q3 core revenue growth guidance: 2% to 3%
  • Full-year 2026 core revenue growth guidance: 3% to 4%
  • Adjusted EPS guidance for 2026: $8.45 to $8.60

Challenges cited include pricing pressures in China’s diagnostics market and inconsistent equipment demand, creating volatility in quarterly results and increased sensitivity to future guidance.

Year-to-date, Danaher's stock has declined 11.78%, with a market capitalization near $144.3 billion and daily average trading volume of approximately 4.6 million shares.

Material is for informational purposes and is not a financial recommendation.